11.1 Patient Safety: Drug Interactions and Toxicity

11.1 Patient Safety: Drug Interactions and Toxicity

Quick Answer: Patient safety in pharmacy is built on the medication use process (prescribing, transcribing, dispensing, administration, monitoring), focused attention to high-alert medications (anticoagulants, insulin, opioids, chemotherapy, concentrated electrolytes), disciplined drug interaction screening rated by likelihood × severity, and rapid recognition of toxicity syndromes (digoxin, lithium, methotrexate, acetaminophen). Layered system defenses — CPOE with clinical decision support (CDS), barcode medication administration (BCMA), independent double checks, and REMS — reduce harm at scale.

The Medication Use Process and Error Points

Medication use is a five-stage process: prescribing (drug, dose, route, frequency selected), transcribing (order communicated — written, verbal, or electronic), dispensing (selection, preparation, labeling), administration (drug given to the patient), and monitoring (response assessed, adverse events detected). Errors cluster at prescribing (wrong drug, wrong dose, allergy missed) and administration (wrong patient, wrong time, wrong route), but harm is intercepted most efficiently at order review by the pharmacist. The Swiss cheese model explains how layered defenses (CPOE, pharmacist review, BCMA, double check) each have holes; harm occurs only when the holes align.

High-Alert Medications

High-alert medications are not necessarily the most frequently implicated in errors, but they carry a disproportionate risk of catastrophic harm when an error occurs. The Institute for Safe Medication Practices (ISMP) maintains the canonical list.

Drug Interaction Screening and Significance Rating

Drug interaction alerts flood community and hospital pharmacies; most are low clinical significance and contribute to alert fatigue. A clinically significant interaction is rated by the product of likelihood (probability the interaction will occur and produce an effect) and severity (potential harm). Most systems use a three-tier severity rating: major (life-threatening or permanent harm — intervene), moderate (may cause deterioration or require therapy change — intervene based on judgment), and minor (nuisance, minimal clinical effect — usually ignore).

Pharmacists triage alerts by asking: Is the patient actually on the interacting combination? Is the dose and duration clinically meaningful? Does the patient have risk factors (age, renal/hepatic impairment, polypharmacy)? What monitoring or substitution resolves the issue?

Mechanisms of Clinically Significant Interactions

CYP450 Induction and Inhibition

Inducers (rifampin, phenytoin, carbamazepine, phenobarbital, St. John's wort) upregulate CYP450 expression over days to weeks, lowering substrate levels. Classic example: rifampin + warfarin requires warfarin dose increases of 2–5× during co-administration, then a sharp drop when rifampin stops.

Inhibitors (clarithromycin, erythromycin, fluconazole, ketoconazole, itraconazole, voriconazole, ritonavir, cimetidine, grapefruit juice) block enzyme activity rapidly (often within hours to days), raising substrate levels. Clarithromycin + simvastatin markedly raises statin exposure and precipitates rhabdomyolysis; azole antifungals and macrolides (except azithromycin) similarly interact with statins. Fluconazole + warfarin raises INR.

P-glycoprotein (P-gp) Interactions

P-glycoprotein (ABCB1) is an efflux transporter at the gut, kidney, and blood-brain barrier. Inhibitors (amiodarone, clarithromycin, verapamil, dronedarone, cyclosporine) raise levels of P-gp substrates. Classic example: amiodarone + digoxin — digoxin levels roughly double, and the combination also raises digoxin toxicity risk through additive bradycardia; reduce digoxin dose by 50% when starting amiodarone. Dabigatran levels rise with P-gp inhibitors (verapamil, amiodarone, dronedarone, ketoconazole) — dose adjustment is required.

Additive QT Prolongation

Drugs that prolong the QT interval (azithromycin, clarithromycin, fluoroquinolones, ondansetron, haloperidol, methadone, amiodarone, sotalol, certain antipsychotics) combine additively, raising torsades de pointes risk, particularly with hypokalemia, hypomagnesemia, bradycardia, and structural heart disease. Azithromycin + ondansetron in a patient with risk factors is a clinically significant combination — substitute the antiemetic (e.g., palonosetron with less QT effect) or use a non-QT-prolonging antibiotic where possible.

Serotonin Syndrome

Serotonin syndrome results from excess serotonergic activity and presents with clonus (most specific sign), hyperreflexia, diaphoresis, agitation, tremor, hyperthermia, and autonomic instability. Classic precipitant pairs: SSRIs/SNRIs + tramadol (serotonergic opioid), SSRIs + linezolid (a reversible MAO inhibitor), SSRIs + MAO inhibitors, SSRIs + triptans (controversial but flagged), meperidine + MAO inhibitors (strictly contraindicated). Onset is usually within 24 hours of adding or increasing the serotonergic agent. Management: discontinue the offending drugs, supportive care, cyproheptadine for moderate-to-severe cases, benzodiazepines for agitation and to reduce neuromuscular hyperactivity.

Hypoglycemia from Drug Interactions

Sulfonylureas + fluoroquinolones: fluoroquinolones (especially gatifloxacin, now withdrawn, but also levofloxacin and ciprofloxacin) can potentiate insulin release and impair glucose regulation, leading to hypoglycemia in patients on sulfonylureas or insulin. Monitor glucose closely, consider alternative antibiotic, and educate the patient on hypoglycemia symptoms.

Toxicity Recognition and Management

Digoxin Toxicity

Digoxin has a narrow therapeutic window (typical target 0.5–0.9 ng/mL for heart failure, higher historically for AF). Chronic toxicity presents with GI symptoms (nausea, vomiting, anorexia), visual disturbances (yellow-green halos, blurred vision — xanthopsia), confusion, and arrhythmias (premature ventricular contractions, atrial tachycardia with block, bradycardia). Precipitants include hypokalemia (potentiates digoxin binding), hypomagnesemia, hypercalcemia, and renal dysfunction. Treatment: stop digoxin, correct electrolytes, manage arrhythmias (avoid calcium channel blockers — they can worsen AV block; magnesium is useful for torsades), and administer digoxin-specific antibody fragments (Fab) for life-threatening arrhythmias, hyperkalemia >5.5 mEq/L, hemodynamic instability, or serum digoxin >10 ng/mL (acute) or >6 ng/mL (chronic).

Lithium Toxicity

Lithium toxicity presents along a progression: mild (fine tremor, GI upset, mild lethargy), moderate (coarse tremor, ataxia, dysarthria, confusion), severe (seizures, arrhythmias, hyperthermia, coma). Acute overdose initially shows GI prominence then neurologic; chronic toxicity is dominated by neurologic signs. Precipitants: dehydration, hyponatremia (sodium and lithium share renal handling), thiazide diuretics, NSAIDs, ACE inhibitors, renal dysfunction. Treatment: stop lithium, IV normal saline, hemodialysis for severe toxicity (seizures, decreased consciousness, serum lithium >4 mEq/L acute or >2.5 mEq/L chronic with symptoms).

Methotrexate Toxicity

Methotrexate toxicity (especially high-dose oncology or accidental daily dosing of weekly regimens) presents with mucositis, GI ulceration, myelosuppression (pancytopenia), hepatotoxicity, and renal failure from intrarenal precipitation. Treatment: folinic acid (leucovorin) rescue — provides the reduced folate that bypasses the dihydrofolate reductase block; glucarpidase for high-dose toxicity with renal failure; hydration and alkalinization of urine. The classic error is dispensing daily instead of weekly methotrexate for rheumatoid arthritis or psoriasis — a sentinel event that ISMP has flagged for decades.

Acetaminophen Hepatotoxicity

Acetaminophen overdose depletes glutathione and the toxic metabolite NAPQI accumulates, causing centrilobular hepatic necrosis. Acute single ingestion ≥150 mg/kg (or ≥7.5 g in adults) is concerning; staggered or chronic ingestions are harder to assess. Use the Rumack-Matthew nomogram (apply only to acute single ingestions with a known time of ingestion and a level drawn ≥4 hours post-ingestion): levels above the treatment line warrant N-acetylcysteine (NAC). NAC can be given oral (72-hour protocol) or IV (21-hour protocol). If the time of ingestion is unknown or chronic, use NAC if there is evidence of hepatotoxicity (AST/ALT elevated, detectable acetaminophen level) or substantial ingestion history.

Medication Error Prevention

Computerized Physician Order Entry (CPOE) and Clinical Decision Support (CDS)

CPOE replaces handwritten orders with electronic entry, eliminating transcription errors and legibility problems. CDS layered on top provides allergy checks, dose range checks, duplicate therapy alerts, drug interaction alerts, renal/hepatic dose guidance, and formulary alternatives. Effective CDS is specific, actionable, and filtered — too many low-value alerts cause alert fatigue and clinicians override critical warnings.

Barcode Medication Administration (BCMA)

BCMA requires the nurse to scan the patient wristband and the medication barcode before administration, verifying the five rights (right patient, drug, dose, route, time) at the bedside. BCMA reduces administration errors by roughly 50%.

Independent Double Checks

An independent double check is a process in which a second qualified person independently verifies the drug, dose, calculation, and pump programming without being told what the first person concluded. They are required for high-alert medications (insulin, heparin, chemotherapy, opioids) in many institutions. They are not foolproof — they fail when the second checker is rushed or biased by being told the answer.

Black Box Warnings and REMS

A black box warning (FDA's strongest labeling warning) highlights serious or life-threatening risks. A Risk Evaluation and Mitigation Strategy (REMS) is a formal FDA-required program that goes beyond labeling to control specific risks. Examples: ER/LA opioid REMS (prescriber education, patient counseling document), transmucosal immediate-release fentanyl (TIRF) REMS (restricted to opioid-tolerant patients), isotretinoin REMS (iPLEDGE — pregnancy prevention), clozapine REMS (ANC monitoring), thalidomide/lenalidomide REMS (pregnancy prevention).

ADE Reporting and Improvement

Adverse drug events (ADEs) are reportable to FDA MedWatch; serious unlabeled reactions should be reported. The Joint Commission publishes Sentinel Event Alerts and National Patient Safety Goals that frequently target high-alert medications, look-alike/sound-alike (LASA) drugs, and anticoagulation. Root cause analysis (RCA) is performed after serious events to identify system causes rather than blame individuals; Failure Mode and Effects Analysis (FMEA) is prospective — anticipating where a process could fail before harm occurs.